DFFN VS CVKD Stock Comparison

Performance

DFFN
10/100

DFFN returned -61.80% in the last 12 months. Based on SPY's performance of -8.71%, its performance is below average giving it a score of 10 of 100.

CVKD
10/100

CVKD returned -92.65% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

DFFN
75/100

1 analysts offer 12-month price targets for DFFN. Together, they have an average target of 0, the most optimistic target put DFFN at 0 within 12-months and the most pessimistic has DFFN at 0. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

CVKD

"Analyst Price Targets" not found for CVKD

Technicals

DFFN
14/100

DFFN receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

CVKD
11/100

CVKD receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

DFFN
10/100

DFFN has missed earnings 7 times in the last 20 quarters.

CVKD

"Earnings" not found for CVKD

Profit

DFFN
10/100

Out of the last 20 quarters, DFFN has had 0 profitable quarters and has increased their profits year over year on 0 of them.

CVKD
30/100

Out of the last 7 quarters, CVKD has had 1 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

DFFN
48/100

DFFN has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

CVKD
26/100

CVKD has had a lower than average amount of volatility over the last 12 months giving it a score of 26 of 100.

All score calculations are broken down here to help you make more informed investing decisions

DIFFUSION PHARMACEUTICALS INC Summary

Nasdaq / DFFN

Healthcare

Biotechnology

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.

Cadrenal Therapeutics, Inc. Common Stock Summary

Nasdaq / CVKD

Healthcare

Biotechnology

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Power up your portfolio